Skip to content
HomeProjectsPANCAID – PANcreatic CAncer Initial Detection via liquid biopsy

PANCAID – PANcreatic CAncer Initial Detection via liquid biopsy




Awareness and Diagnosis; Treatment


January 2023 - December 2027

Project website 

Downloadable documents

Press Release


PANCAID – PANcreatic CAncer Initial Detection via liquid biopsy

Project Summary:  

Pancreatic Cancer (PDAC) is usually detected at late stages and most patients die within one year after diagnosis. In PANCAID we will therefore develop a blood test for early detection of PDAC. Despite tremendous technological advances in Liquid Biopsy Diagnostics (LBx), this goal is very ambitious because small tumors release only minute amounts of cells or cellular products (e.g. DNA, RNA, protein, metabolites) into the circulation. Thus, tests with a high sensitivity are required but increases in sensitivity are usually achieved on the expense of reduced specificity which can lead to significant overdiagnosis leading to unnecessary stress for the individuals with a false-positive blood test and high costs for the health system. In PANCAID, we will therefore establish a blood test with high accuracy by analyzing large cohorts of patients with PDAC and its precursor lesions, individuals at risk to develop PDAC and appropriate age-matched control groups (healthy and non-cancer diseases frequent in the target population).

Ambitious objectives of PANCAID include:

(1) establishment of a unique resource of blood samples of early PDAC and risk groups (WP1),

(2) Establishment of a breakthrough blood test for early diagnosis of PDAC (WP2);

(3) Identification of the best composite biomarker panel by integrating multimodal features in an AI-assisted computational analysis;

Project Coordinator:

Universitätsklinikum Hamburg-Eppendorf (Germany)

(4) Analysis of the socio-economic impact of early PDAC diagnosis (WP4); and

(5) Definition of the ethics parameter relevant to early PDAC detection (WP5).